NCT00004700已完成2 期
Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 16
研究概览
简要总结
OBJECTIVES:
Evaluate the safety and efficacy of long term recombinant human insulin-like growth factor I in children with hyperinsulinism.
详细描述
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, cross-over study.
Patients are randomized to receive recombinant human insulin-like growth factor I (IGF-I) or placebo subcutaneously twice daily for 4 weeks. After a 2 week washout period, patients are crossed over to the other regimen for an additional 4 weeks.
Completion date provided represents the completion date of the grant per OOPD records
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 3 Months 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PROTOCOL ENTRY CRITERIA:
- •-Disease Characteristics-- Diagnosis of hyperinsulinism (i.e., evidence of fasting hypoglycemia with inadequate suppression of insulin, normal pituitary and adrenal function, and increased insulin action) Suboptimal control of blood sugar (i.e., inability to fast at least 10 hours with a blood sugar of 60 mg/dL or greater) --Prior/Concurrent Therapy-- See Disease Characteristics --Patient Characteristics-- Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No other major medical conditions No known adverse reaction to recombinant human insulin-like growth factor I
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin ResistanceHyperglycemiaInsulin ResistanceNCT00004419Beth Israel Deaconess Medical Center18
终止
1 期
A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Diffuse Cutaneous Systemic SclerosisNCT04478994Amgen3
已完成
不适用
Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's SyndromeWerner's SyndromeNCT00004815National Center for Research Resources (NCRR)1
已完成
2 期
Long-Term Treatment With rhIGF-1 in GHISGrowth Hormone Insensitivity SyndromeNCT00571727Ipsen92
已完成
不适用
Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With HyperinsulinismHyperinsulinismNCT00004825FDA Office of Orphan Products Development10